retatrutide clinical trial sign up VisualAbstract: Retatrutide reduces body weight by 17.5% in patients with obesity

Today we shared new results on retatrutide, an investigational, first-of-its-kind treatment we're studying in adults with obesity or overweight with at least one weight-related comorbidity. Read more about the Phase 3 findings:

27.08

★★★★☆4.8 (126)

Retatrutide FDA Approval Status 2026: Everything We Know So Far

28.50

★★★★★4.9 (98)

The Retatrutide Dosage Chart: A Guide On Retatrutide Dosage

25.36

★★★★★5.0 (157)

Reta clinical trial data & dosing — a must read Retatrutide (Reta) isn't just another GLP-1. It's a triple-agonist peptide studied in Phase 3 trials for metabolic health — targeting GLP-1, GIP,

23.16

★★★★★4.7 (84)

Everyone keeps asking me the same question: **“When will RETATRUTIDE be available?”** Here's the honest, evidence-based answer: **Retatrutide is NOT FDA approved and is NOT available right now.** Yes—the clinical trial results

25.21

★★★★★4.9 (203)

Today's TRIUMPH-4 results are a clear signal: the next generation of incretin medications will be more powerful than anything we've seen before. Retatrutide is showing nearly 30% body-weight reduction in clinical trials,

26.23

★★★★★5.0 (176)

Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials - Giblin - 2026 - Diabetes, Obesity and Metabolism

24.48

★★★★★4.8 (132)